Appili Therapeutics Inc Class A (APLIF)
OTHER OTC:APLIF
Want to see APLIF full AI Analyst Report?
APLIF Stock Chart & Stats
$0.01
>-$0.01(-8.10%)
At close: 4:00 PM EST
$0.01
>-$0.01(-8.10%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.03
Previous CloseN/A
Volume100.00
Average Volume (3M)43.77K
Market Cap
$1.88M
Enterprise Value$14.82M
Total Cash (Recent Filing)$212.75K
Total Debt (Recent Filing)$12.46M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Jul 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding128,366,120
10 Day Avg. Volume6,020
30 Day Avg. Volume43,769
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.39
Price to Sales (P/S)5.13
P/FCF Ratio-1.70
Enterprise Value/Market Cap7.86
Enterprise Value/Revenue71.81
Enterprise Value/Gross Profit74.23
Enterprise Value/Ebitda-9.32
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Infectious-disease PipelineAppili’s dedicated pipeline in antibacterial, antiviral and antifungal therapies targets clear unmet needs in infectious disease. This focused strategy creates durable strategic clarity, helps prioritize R&D spend efficiently, and increases attractiveness for long-term partnerships and public-health funding.
High Reported Gross MarginReported high gross margins indicate attractive unit economics for drug candidates if they reach commercialization. Durable gross-margin strength supports operating leverage as sales scale, improves potential profitability profiles, and enhances prospects for licensing or partner deals.
Reduced Cash Burn TrendA trend toward lower cash burn versus earlier periods extends runway and reflects better operational control. If sustained, this improvement reduces near-term financing needs, enabling more stable execution of clinical programs and lowering the frequency of dilutive capital raises over the next several quarters.
Bears Say
Stressed Balance SheetNegative equity combined with roughly $12.5M of debt versus very small assets creates acute financing and solvency risk. This thin balance sheet constrains ability to fund trials internally, increases refinancing and dilution risk, and can materially impede long-term program execution if markets tighten.
Very Small Revenue Vs Large LossesTTM revenue near $0.2M against approximately -$3.0M net loss shows the company lacks commercial scale and is not covering operating costs. Persistent high losses mean continued reliance on external capital, elevating execution risk and making long-term planning dependent on successful funding or partnerships.
Inconsistent Cash GenerationSlightly negative and volatile cash flows indicate the company cannot reliably self-fund operations. This inconsistency forces recurring capital raises, complicates multi-stage clinical development planning, and can delay programs or weaken negotiating leverage with collaborators over the medium term.
Appili Therapeutics Inc Class A News
APLIF FAQ
What was Appili Therapeutics Inc Class A’s price range in the past 12 months?
Appili Therapeutics Inc Class A lowest stock price was <$0.01 and its highest was $0.03 in the past 12 months.
What is Appili Therapeutics Inc Class A’s market cap?
Appili Therapeutics Inc Class A’s market cap is $1.88M.
When is Appili Therapeutics Inc Class A’s upcoming earnings report date?
Appili Therapeutics Inc Class A’s upcoming earnings report date is Jul 01, 2026 which is in 56 days.
How were Appili Therapeutics Inc Class A’s earnings last quarter?
Appili Therapeutics Inc Class A released its earnings results on Feb 12, 2026. The company reported -$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.005.
Is Appili Therapeutics Inc Class A overvalued?
According to Wall Street analysts Appili Therapeutics Inc Class A’s price is currently Overvalued.
Does Appili Therapeutics Inc Class A pay dividends?
Appili Therapeutics Inc Class A does not currently pay dividends.
What is Appili Therapeutics Inc Class A’s EPS estimate?
Appili Therapeutics Inc Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Appili Therapeutics Inc Class A have?
Appili Therapeutics Inc Class A has 128,366,120 shares outstanding.
What happened to Appili Therapeutics Inc Class A’s price movement after its last earnings report?
Appili Therapeutics Inc Class A reported an EPS of -$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Appili Therapeutics Inc Class A?
Currently, no hedge funds are holding shares in APLIF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Appili Therapeutics Inc Class A
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.